IMMX
NASDAQ · Biotechnology
Immix Biopharma Inc
$8.32
-0.23 (-2.69%)
Open$8.61
Previous Close$8.55
Day High$8.72
Day Low$8.21
52W High$12.14
52W Low$1.94
Volume—
Avg Volume1.63M
Market Cap691.97M
P/E Ratio—
EPS$-0.91
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+44.0% upside
Current
$8.32
$8.32
Target
$11.98
$11.98
$7.05
$11.98 avg
$14.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 163.82M | 157.27M | 158.27M |
| Net Income | -44,702,535 | -44,556,024 | -43,506,106 |
| Profit Margin | -27.3% | -28.3% | -27.5% |
| EBITDA | -45,867,623 | -43,115,764 | -48,402,369 |
| Free Cash Flow | -22,695,190 | -23,234,474 | -24,663,069 |
| Rev Growth | +3.0% | +15.0% | +13.1% |
| Debt/Equity | 0.40 | 0.42 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |